RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus.
Staphylococcus aureus is a prevalent cause of bacterial infections associated with indwelling medical devices. RNA III inhibiting peptide (RIP) is known to inhibit S. aureus pathogenesis by disrupting quorum-sensing mechanisms. RIP was tested in the present study for its ability to inhibit S. aureus biofilm formation in a rat Dacron graft model. The activity of RIP was synergistic with those of antibiotics for the complete prevention of drug-resistant S. aureus infections.
Giacometti
Andrea
A
Institute of Infectious Diseases and Public Health, Ancona, Italy.
Cirioni
Oscar
O
Gov
Yael
Y
Ghiselli
Roberto
R
Del Prete
Maria Simona
MS
Mocchegiani
Federico
F
Saba
Vittorio
V
Orlando
Fiorenza
F
Scalise
Giorgio
G
Balaban
Naomi
N
Dell'Acqua
Giorgio
G
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D019072:Antibiotic Prophylaxis; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development*; D002450:Cell Communication / Q000187:drug effects; D015169:Colony Count, Microbial; D004357:Drug Synergism; D008297:Male; D008826:Microbial Sensitivity Tests; D009842:Oligopeptides / Q000494:pharmacology*; D011093:Polyethylene Terephthalates; D019736:Prostheses and Implants / Q000382:microbiology*; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development*
D000900:Anti-Bacterial Agents; D009842:Oligopeptides; D011093:Polyethylene Terephthalates; C111711:RNAIII inhibiting peptide